Share

May 2017; 4 (3) ArticleOpen Access

Microstructural visual system changes in AQP4-antibody–seropositive NMOSD

Frederike C. Oertel, Joseph Kuchling, Hanna Zimmermann, Claudia Chien, Felix Schmidt, Benjamin Knier, Judith Bellmann-Strobl, Thomas Korn, Michael Scheel, Alexander Klistorner, Klemens Ruprecht, Friedemann Paul, Alexander U. Brandt
First published February 22, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000334
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
984

Share

Article Information

vol. 4 no. 3 e334
DOI: 
https://doi.org/10.1212/NXI.0000000000000334
PubMed: 
28255575
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received December 1, 2016
  • Accepted in final form January 10, 2017
  • First Published February 22, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Frederike C. Oertel*,
    2. Joseph Kuchling, MD*,
    3. Hanna Zimmermann, MEng,
    4. Claudia Chien, MSc,
    5. Felix Schmidt, MD,
    6. Benjamin Knier, MD,
    7. Judith Bellmann-Strobl, MD,
    8. Thomas Korn, MD,
    9. Michael Scheel, MD,
    10. Alexander Klistorner, MD,
    11. Klemens Ruprecht, MD,
    12. Friedemann Paul, MD and
    13. Alexander U. Brandt, MD
  1. Frederike C. Oertel*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Joseph Kuchling, MD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. JK received congress registration fee from Biogen andresearch support from Krankheitsbezogenes KompetenznetzMultiple Sklerose (KKNMS).

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Hanna Zimmermann, MEng,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Commercial, Speaker honoraria from Teva(2) Commercial, Speaker honoraria from Bayer

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Claudia Chien, MSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Felix Schmidt, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I received 130 Euros from Genzyme for a 5 min case presentation during a Meeting for neurologists sponsored by Genzyme.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Benjamin Knier, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Bayer, Travel Compensation(2) Merck Serono, Travel Compensation(3) ECTRIMS (non-profit), travel grant(4) Neurowind e.V. (non-profit), travel grant

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Kompetenznetz Multiple Sklerose (KKNMS), research grantfrom the Bundesministerium f?r Bildung und Forschung

    Research Support, Academic Entities:

    1. Kommission f?r Klinische Foschung (KKF), intramuralresearch grant within the Technical University of Munich

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Judith Bellmann-Strobl, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. speaking fees and travel grants from Bayer Healthcare, sanofi-aventis/Genzyme, and Teva Pharmaceuticals

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Thomas Korn, MD,
    9. Scientific Advisory Boards:

    1. (1) German MS society(2) Merck Serono(3) Novartis(4) Biogen

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Biogen(2) Novartis(3) Merck Serono(4) Bayer

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen

    Research Support, Government Entities:

    1. (1) German Research Council(2) German Ministry of Education and Research(3) European Research Council

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Else-Kr?ner-Fresenius Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Michael Scheel, MD,
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. 1) Patent for manufacturing of phantoms for computedtomography imaging with 3D printing technology

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) Federal Ministry of Economics and Technology - EXISTProgramme Grant 03EFEBE079

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Alexander Klistorner, MD,
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. 1. “Electrophysiological visual field measurement”Klistorner and Graham 1999, PCT/AU99/003402. “Method and apparatus for objectiveelectrophysiological assessment of visual function”Klistorner and Graham 2001, PCT/AU01/004233. ?Stimulus Method for Multifocal Visual EvokedPotential? Klistorner and Graham (Australian PatentApplication No 2007900803) 4. ?Flexible electrode assembly and apparatus formeasuring electrophysiological signals? Cheng, Klistorner,Graham (Australian Provisional Patent # 2006904755) 5. ?Apparatus for measuring electrophysiological signals?Cheng, Klistorner, Dyer - Australian Design No. 310666. 6. ? Flexible printed circuit board electrode assembly?Cheng, Klistorner, Dyer - Australian Design No. 311943.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. Sydney University Foundation for Medical Research2. Sydney eye hospital foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Klemens Ruprecht, MD,
    12. Scientific Advisory Boards:

    1. (1)sanofi-aventis/Genzyme(2)Novartis(3)Roche

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1)Bayer Healthcare, travel and speaker honoraria(2)Biogen Idec, travel and speaker honoraria(3)Merck Serono, travel and speaker honoraria(4)sanofi-aventis/Genzyme, travel and speaker honoraria(5)Teva Pharmaceuticals, travel and speaker honoraria(6)Novartis, travel and speaker honoraria(7)Guthy Jackson Charitable Foundation, travel honoraria

    Editorial Boards:

    1. (1) PLOS ONE, Academic Editor, since 2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Neurologie in Frage und Antwort, Elsevier, 2000-2015

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis

    Research Support, Government Entities:

    1. (1)German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Friedemann Paul, MD and
    13. Scientific Advisory Boards:

    1. Novartis OCTIMS study steering committeeMedImmune steering committee

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire

    Editorial Boards:

    1. Academic Editor, PLoS ONEAssociate Editor, Neurology Neuroimmunology andNeuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono

    Research Support, Government Entities:

    1. German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry ofEducation and Research (BMBF Competence Network MultipleSclerosis), Arthur Arnstein Stiftung Berlin, EU FP7Framework Program (combims.eu)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Arthur Arnstein Foundation Berlin, Guthy JacksonCharitable Foundation, National Multiple Sclerosis Societyof the USA

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Alexander U. Brandt, MD
    14. Scientific Advisory Boards:

    1. (1) Biogen VISION study, scientific advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Novartis, funding for travel to conference(2) Biogen, funding for travel to conference(4) Teva, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Pending patent Method and System For OpticNerve Head Shape Quantification.(2) Pending patent Perceptive Visual Computingbased Postural Control Analysis.(3) Pending patent Multiple Sclerosis Biomarker.(4) Pending patent Perceptive Sleep MotionAnalysis

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Nexus, Hospital Information Systems(2) Motognosis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis Pharma(2) Biogen Idec

    Research Support, Government Entities:

    1. (1) BMWi, ZIM KF2443803KJ, PI, two years(2) BMWi, ZIM KF2291305AK3, Co-I, one year(3) BMWI, EXIST-FT 03EFEBE079, PI, two years(4) BMBF, NEU2 N2-ADVISIMS, Co-I, three years

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) The Guthy Jackson Charitabke Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. (1) Motognosis, 2014 (ongoing)

    Legal Proceedings:

    1. NONE

  1. From the NeuroCure Clinical Research Center (F.C.O., J.K., H.Z., C.C., F.S., J.B.-S., M.S., F.P., A.U.B.), and Department of Neurology (J.K., F.S., J.B.-S., K.R., F.P.), Charité—Universitätsmedizin Berlin; Department of Neurology (B.K., T.K.), Klinikum rechts der Isar, and Department of Experimental Neuroimmunology (T.K.), Technische Universität München; Munich Cluster for Systems Neurology (SyNergy) (T.K.), Germany; Clinical Ophthalmology and Eye Health (A.K.), Central Clinical School, Save Sight Institute, Sydney, Australia; and Experimental and Clinical Research Center (F.P.), Max Delbrueck Center for Molecular Medicine and Charité—Universitätsmedizin Berlin, Germany.
  1. Correspondence to Dr. Brandt: alexander.brandt{at}charite.de
View Full Text

Article usage

Article usage: February 2017 to July 2020

AbstractFullPdfSource
Feb 201715524967Highwire
Mar 20173848651Highwire
Mar 201706841pmc
Apr 201734724622Highwire
Apr 2017172628pmc
May 201733023745Highwire
May 2017183437pmc
Jun 2017116386Highwire
Jun 2017162527pmc
Jul 201758335Highwire
Jul 201781721pmc
Aug 201748308Highwire
Aug 2017112834pmc
Sep 201727222Highwire
Sep 2017152739pmc
Oct 201739181Highwire
Oct 2017102222pmc
Nov 201735166Highwire
Nov 2017181926pmc
Dec 2017103814Highwire
Jan 201810425Highwire
Feb 2018144817Highwire
Mar 2018157812Highwire
Apr 2018155815Highwire
Apr 2018102023pmc
May 20186369Highwire
Jun 20185397Highwire
Jun 201871517pmc
Jul 20188435Highwire
Aug 201886314Highwire
Aug 201851516pmc
Sep 201842312Highwire
Oct 201834712Highwire
Nov 201862610Highwire
Dec 20183282Highwire
Jan 20196255Highwire
Feb 20199439Highwire
Mar 2019177023Highwire
Apr 20197199Highwire
May 2019167317Highwire
Jun 2019125419Highwire
Jul 201963310Highwire
Aug 20191616012Highwire
Sep 201913418Highwire
Oct 2019103910Highwire
Nov 201974017Highwire
Dec 2019186625Highwire
Jan 202033816Highwire
Feb 202066822Highwire
Mar 20201495918Highwire
Apr 2020954028Highwire
May 2020442824Highwire
Jun 20201218619Highwire
Jul 2020103515Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Topics Discussed

Alert Me